Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. VRP.L Share Price
  4. VRP.L Share Regulatory News

Pin to quick picksVRP.L Regulatory News (VRP)

VRP.L Information
  • There is currently no data for VRP
123456789
Date   Source Headline
10th Jan 202011:00 pmGNWVerona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy
7th Jan 20207:00 amGNWVerona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations
28th Nov 201910:25 amGNWHolding(s) in Company TR-1: Standard form for notification of major holdings
27th Nov 20197:00 amGNWVerona Pharma plc: Grant of Options to PDMR
18th Nov 20197:00 amGNWVerona Pharma plc: PDMR Dealing – Purchase by Chairman
14th Nov 20197:00 amGNWVerona Pharma plc: PDMR Dealing – Purchase by Chairman
13th Nov 20197:00 amGNWVerona Pharma to Present at Jefferies 2019 London Healthcare Conference
11th Nov 20197:00 amGNWVerona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New York
5th Nov 20197:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019
29th Oct 20197:00 amGNWVerona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development Update
17th Oct 20197:00 amGNWVerona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD
15th Oct 20197:00 amGNWVerona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
19th Sep 20197:00 amGNWVerona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
9th Sep 20192:33 pmGNWHolding(s) in Company TR-1: Standard form for notification of major holdings
3rd Sep 20197:00 amGNWVerona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
9th Aug 20199:35 amGNWVerona Pharma plc: PDMR Dealing
6th Aug 20197:00 amGNWVerona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019
5th Aug 20197:00 amGNWVerona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
30th Jul 20197:00 amGNWVerona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development Update
24th Jul 20197:00 amGNWVerona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference
25th Jun 20197:00 amGNWVerona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine
4th Jun 20197:00 amGNWVerona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
30th May 20197:00 amGNWVerona Pharma to Present at Jefferies 2019 Global Healthcare Conference
29th May 201911:07 amRNSPDMR Dealing
20th May 20193:15 pmGNWVerona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
7th May 201912:51 pmGNWResult of AGM
7th May 20197:00 amGNWVerona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
7th May 20197:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
2nd May 201912:00 pmGNWVerona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
1st May 20197:00 amGNWVerona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update
1st May 20197:00 amGNWVerona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker
25th Apr 201912:07 pmGNWVerona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019
4th Apr 20197:00 amGNWGrant of Options and RSUs and PDMR Dealings
26th Mar 20197:00 amGNWVerona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
25th Mar 20197:00 amGNWPDMR Dealing
22nd Mar 20194:00 pmGNW2018 Annual Report and Accounts and Notice of AGM 
11th Mar 20199:48 amGNWPDMR Dealing
7th Mar 20198:14 amGNWPDMR Dealing
5th Mar 20199:48 amGNWPDMR Dealing
4th Mar 20197:00 amGNWVerona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
28th Feb 20197:00 amGNWVerona Pharma to Present at Cowen and Company 39th Annual Health Care Conference
26th Feb 20197:00 amGNWVerona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update
20th Feb 20197:00 amGNWVerona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update
4th Feb 20197:00 amGNWVerona Pharma to Present at Upcoming Investor Conferences
14th Jan 20197:00 amGNWVerona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
9th Jan 20191:00 pmGNWVerona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554
17th Dec 20185:20 pmGNWVerona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
17th Dec 20187:00 amGNWVerona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
6th Nov 20187:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018
31st Oct 20187:00 amGNWVerona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment
123456789

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
0NL1
Pva Tepla Ord
LSE
0.00%
EIG
EI Group
LSE
0.00%
CLL
CLL.L
LSE
0.00%
CUSH.PL
Crushmetric Group Limited
AQSE
0.00%
TPT
Topps Tiles
LSE
-2.20%
Trending
BSFA
Bio-Sustainable Future Enterprises
LSE
-5.00%
GEX
Georgina Energy
LSE
2.54%
ALRT
Defence Holdings
LSE
0.00%
MAC
Marechale Cap.
LSE
21.92%
PANR
Pantheon Resources plc
LSE
21.38%